Product image of Minidiab (Glipizide) supplied by GNH India

Minidiab

Active Ingredient:
Glipizide
Origin:
EU

Minidiab (Glipizide)

Glipizide, the active ingredient in Minidiab, is a sulfonylurea presented as a tablet for oral use. It treats type 2 diabetes mellitus by stimulating insulin release in adult patients.
GNH India supplies Minidiab as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Pfizer Italia S.R.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Glipizide is used in the management of type 2 diabetes mellitus, a disorder of glucose metabolism.

  • Type 2 diabetes mellitus: improves overall glycemic control by increasing endogenous insulin secretion.
  • Hyperglycemia associated with type 2 diabetes: lowers fasting and post‑prandial blood glucose levels.
  • Adjunct to diet and exercise in type 2 diabetes: helps achieve target HbA1c when lifestyle measures alone are insufficient.

How It Works

  • Glipizide binds to the sulfonylurea receptor component of the ATP‑sensitive potassium channel on pancreatic beta cells. This binding closes the channel, causing cell depolarisation, calcium influx and subsequent exocytosis of insulin, thereby raising circulating insulin levels and reducing blood glucose.

Side Effects

Glipizide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Hypoglycemia: feeling of shakiness, sweating, or confusion due to low blood sugar.
  • Weight gain: modest increase in body weight during therapy.
  • Nausea: mild stomach upset or queasiness.
  • Headache: occasional mild to moderate head pain.

Serious or Rare Side Effects

  • Severe hypoglycemia: prolonged low blood glucose requiring medical attention.
  • Allergic reactions: rash, itching, or swelling that may indicate hypersensitivity.
  • Hematologic abnormalities: rare cases of leukopenia or thrombocytopenia.

Precautions & Warnings

Before initiating glipizide therapy, several safety considerations should be observed.

  • Blood glucose monitoring: regularly check glucose levels to avoid hypoglycemia.
  • Renal impairment: dose may need adjustment in patients with reduced kidney function.
  • Elderly patients: start with a lower dose and monitor closely for adverse effects.
  • Sulfonylurea allergy: discontinue if signs of hypersensitivity appear.
  • Concomitant hypoglycemic agents: avoid combining with other insulin‑secretagogues without medical supervision.
  • Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Glipizide can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

  • Insulin or other sulfonylureas: additive risk of severe hypoglycemia.
  • CYP2C9 inhibitors (e.g., fluconazole, amiodarone): increase glipizide plasma concentrations.
  • Alcohol: may potentiate hypoglycemic effect.

Moderate Interactions (Monitor Closely)

  • Warfarin: glipizide may enhance anticoagulant effect, requiring INR monitoring.
  • Beta‑blockers: may mask hypoglycemia symptoms, necessitating closer glucose surveillance.

Frequently Asked Questions

Minidiab contains glipizide, an oral antidiabetic medication indicated for the treatment of type 2 diabetes mellitus. It helps lower elevated blood glucose by stimulating the pancreas to release more insulin, supporting glycemic control when diet and exercise alone are insufficient.

Glipizide binds to the sulfonylurea receptor on pancreatic beta‑cell potassium channels, causing channel closure, cell depolarisation, and calcium influx. This cascade triggers the release of stored insulin, increasing circulating insulin levels and reducing blood glucose concentrations.

The appropriate dose of Minidiab is determined by a qualified prescriber based on individual patient factors such as blood glucose levels, renal function, and concomitant therapies. Patients should follow the dosing instructions provided by their healthcare professional.

Safety of glipizide in pregnancy or while nursing has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a healthcare provider.

To request Minidiab, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with metformin, another first‑line oral agent, glipizide (Minidiab) directly stimulates insulin secretion, which can lead to faster glucose reduction but carries a higher risk of hypoglycemia. Choice of therapy depends on patient characteristics, tolerance, and physician judgment.

Minidiab should be stored at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the tablets out of reach of children and do not use them after the expiry date printed on the label.

Minidiab is taken orally, usually once daily with breakfast or the first main meal. Tablets should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as skin rash, swelling or anaphylaxis. Patients should seek immediate medical attention if they experience any of these symptoms.

Minidiab is contraindicated in individuals with a known hypersensitivity to glipizide or other sulfonylureas, patients with severe renal or hepatic impairment, and those experiencing diabetic ketoacidosis. Pregnant or nursing women should only use it under strict medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Glipizide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT